Protocol / Research Dosing Guide

Kisspeptin Protocol Guide - Dosing, Reconstitution & Safety

Research-context reference for planning kisspeptin protocols: dosing math by form, reconstitution, supplies by cycle, tachyphylaxis boundaries, and safety. Not medical advice.

Kisspeptin is a signaling peptide that helps turn on the reproductive hormone pathway. It tells the brain to release GnRH, which tells the pituitary gland to release LH and FSH. In men, LH can then tell the testes to make testosterone. In women, LH and FSH help control ovulation and fertility signals.

Most research-use suppliers stock kisspeptin-10. Many human studies used kisspeptin-54. The difference matters because kisspeptin-10 clears fast, with a half-life of about 4 minutes in blood after IV dosing. Kisspeptin-54 lasts longer, with a half-life of about 28 minutes after subcutaneous dosing.

• Route
  Subcutaneous (SC), meaning under the skin, in research-use protocols. IV infusion is used in clinical trials only.
• Form choice
  Kisspeptin-10 is shorter-acting; kisspeptin-54 is the form used in human trials.
• Measure
  Use vial concentration (mg/mL) and U-100 syringe units for the dose.
• Testosterone pathway
  Kisspeptin may raise testosterone indirectly by raising LH first. It does not act like testosterone itself.
• Cycle structure
  Use short pulses or short cycles. Continuous exposure can make the signal fade, a problem called desensitization.
• Research status
  Not FDA-approved. Research-use only.

Disclaimer
This page is an educational research reference and is not medical advice. No kisspeptin product is FDA-approved. Information is for research-context planning only.

Kisspeptin Dosing Protocol & Schedule
Choose the form that matches the vial being researched. Kisspeptin-10 and kisspeptin-54 are not interchangeable. They last for different amounts of time, and the dose math is different. The schedules below are research-planning ranges, not personal medical advice.

Kisspeptin Protocol 

Kisspeptin-10 (SC)

SC means subcutaneous, or under the skin. This is the shorter-acting form most often stocked by research-use suppliers.

Kisspeptin-10 acts fast and clears fast. After IV dosing, its blood half-life is about 4 minutes. A subcutaneous shot may stretch the effect a little, but the LH and FSH signal is still short. That is why research-use protocols usually use small once-daily or twice-daily SC doses instead of long exposure.

Kisspeptin-10 — Common Research-Context Dosing Ranges

• Approach:  Low-dose pulse
• Typical Range:  50-100 mcg
• Frequency: Once daily SC

Notes

SC means under the skin. Often timed before sleep in research-use planning.

• Approach: Standard pulse
• Typical Range: 100-200 mcg
• Frequency: Once daily SC

Notes

Common community research range, based partly on kisspeptin-54 trial data.

• Approach: Split dose
• Typical Range: 100 mcg
• Frequency: Twice daily SC

Notes

Used when the research plan calls for more frequent LH pulses.

These ranges come from published research and research-use community planning. Human data shows kisspeptin-10 can raise LH in men. Longer exposure may also raise testosterone, but that depends on the testes being able to respond to LH.

Tachyphylaxis with chronic dosing
Continuous exposure can make the LH signal fade. That signal fade is called desensitization or tachyphylaxis. This is why kisspeptin research usually uses short pulses or short cycles instead of nonstop exposure.

Cycle structure and desensitization
Kisspeptin Cycle Guidelines

• Approach: Short pulse cycle
• Active Length: 2-4 weeks
• Off Period: 2-4 weeks

Reasoning

Limits desensitization; aligned with most acute research data

• Approach: Standard cycle
• Active Length: 4-6 weeks
• Off Period: 4 weeks

Reasoning

Most-cited community window; longer cycles risk fading LH response

• Approach: Diagnostic single use
• Active Length: Single dose
• Off Period: N/A

Reasoning

Mirrors clinical use as an LH/FSH stimulation test or IVF trigger

Avoid nonstop exposure. When the kisspeptin signal is pushed too long, LH response can fade.

Kisspeptin Supplies Needed
Plan based on a simple kisspeptin-10 setup: one 100 mcg subcutaneous dose per day from a 10 mg vial mixed with 2 mL bacteriostatic water. At that mix, the vial is 5 mg/mL, so 2 units on a U-100 insulin syringe gives 100 mcg. If your vial size, water amount, or dose is different, redo the math before drawing.

Peptide Vials (10 mg kisspeptin-10)

Each 10 mg vial reconstituted with 2 mL gives 5 mg/mL; one vial supports approximately 100 doses at 100 mcg.

1 vial - 2-8 weeks

2 weeks: 14 doses needed; one vial provides about 100 planned draws before losses; 4 weeks: 28 doses needed; one vial provides about 100 planned draws before losses; 6 weeks: 42 doses needed; one vial provides a large margin for priming losses; 8 weeks: 56 doses needed; one vial still leaves margin for losses and schedule adjustments

Kisspeptin Reconstitution Guide

Kisspeptin ships as a lyophilized (freeze-dried) powder in single-use vials. Reconstitute with bacteriostatic water (BAC water) before drawing any dose. The volume you add determines your final concentration, and that determines how many syringe units equal your target dose.

Common Reconstitution Math (Kisspeptin-10, 10 mg vial)

BAC Water Added - 1.0 mL     Final Concentration - 10 mg/mL     Volume for 100 mcg - 0.01 mL    U-100 Units - 1 unit

BAC Water Added - 1.5 mL      Final Concentration - 6.67 mg/mL   Volume for 100 mcg - 0.015 mL   U-100 Units - 1.5 units

BAC Water Added. - 2.0 mL     Final Concentration - 5 mg/mL       Volume for 100 mcg - 0.02 mL    U-100 Units - 2 units

BAC Water Added - 2.5 mL      Final Concentration - 4 mg/mL       Volume for 100 mcg - 0.025 mL   U-100 Units - 2.5 units

The 2 mL option is the default assumption on this page because it stays under a 3 mL vial limit and keeps 100 mcg equal to 2 syringe units. Smaller draws require careful measurement.

01

Inspect the vial

Confirm the label says kisspeptin (with the form noted: -10 or -54), check the mass, and look for any visible cracks or contamination.

02

Choose your BAC water volume

Use the table above to pick a volume that gives an easy syringe draw for your planned dose.

03

Swab both stoppers

Wipe the BAC water vial stopper and the kisspeptin vial stopper with a fresh alcohol pad each.

04

Draw the BAC water

Pull the planned BAC water volume into a syringe (a larger barrel like 1 mL or 3 mL is easier than insulin syringes for this step).

05

Slowly add water down the vial wall

Inject slowly, aiming for the side of the vial rather than directly onto the lyophilized powder. This protects the peptide from shear stress.

06

Swirl gently to dissolve

Roll or gently swirl the vial. Do not shake. Let it sit until the solution is fully clear.

07

Refrigerate and use

Store reconstituted kisspeptin at 35.6-46.4 F (2-8 C). Use within the supplier's stated beyond-use window when available.

Use a calculator

Reconstitution math is the most common source of dosing errors. A peptide reconstitution calculator is the easiest way to confirm your numbers before drawing.

How Kisspeptin Works

Kisspeptin works near the top of the hormone chain. The brain releases kisspeptin, which turns on GnRH. GnRH then tells the pituitary gland to release LH and FSH. In men, LH tells the testes to make testosterone. FSH helps support sperm production. In women, LH and FSH help control ovulation and follicle growth.

The main receptor is called GPR54, also called KISS1R. A receptor is like a lock on a cell. Kisspeptin is the key that turns that lock. When this signal works, the body can send a stronger LH and FSH message. When this pathway is broken, puberty and fertility signals can fail.

For testosterone research, the key point is simple: kisspeptin does not replace testosterone. It tries to make the body send more LH first. If the testes can respond to LH, testosterone may rise. If the pituitary or testes cannot respond, kisspeptin is unlikely to fix that problem.

Who Kisspeptin Is For and Who Should Avoid It

Human kisspeptin research has focused on healthy adult men, premenopausal women, women with missing periods from low hormone signaling, IVF trigger studies, and men and women with low sexual desire disorder. Outside those research settings, evidence is still limited.

Pregnancy and lactation: Kisspeptin is tied to pregnancy and reproductive cycling. There is no good safety data for use during pregnancy or breastfeeding.

Hormone-sensitive cancers: Kisspeptin can affect sex-hormone signaling. That matters for breast, ovarian, or prostate cancer history.

Active fertility treatment outside a clinical trial: Do not try to copy an IVF trigger protocol without clinical monitoring. Timing, labs, and ultrasound checks matter.

Primary hypogonadism: This means the testes or ovaries are the main problem. Kisspeptin works upstream, so it may not help if the gonads cannot respond.

Pituitary disease: Kisspeptin needs a working pituitary gland to raise LH and FSH.

Pediatric or adolescent use: Kisspeptin is part of puberty timing. It should not be used casually in children or teens.

Heart or vascular concerns: FDA reviewers flagged animal data that may matter for heart and blood-vessel risk. Human relevance is still unclear.

Not a TRT replacement or PCT solution

Kisspeptin is not testosterone replacement. It may raise testosterone indirectly if LH rises and the testes respond, but that is not the same as TRT. Human evidence for post-cycle therapy or fertility restart is still limited.

Kisspeptin Side Effects & Safety

In published human studies, kisspeptin-10 and kisspeptin-54 were generally well tolerated when used short term. The low-desire studies reported no treatment-related serious adverse events. IVF trigger studies reported minor events, but no severe drug-related events clearly tied to kisspeptin-54.

Reported effects from clinical and research-context use

• Mild flushing or warmth shortly after dosing
• Mild injection-site redness or irritation
• Transient headache
• Brief mild nausea
• Short LH and FSH rise, usually followed by a return toward baseline
• Possible testosterone rise after longer exposure in men, if the testes respond to LH
• Theoretical and chronic-use risks

Signal fade with repeated or nonstop exposure. This is called desensitization or tachyphylaxis.

Disruption of normal GnRH pulse timing. GnRH is the brain signal that starts LH and FSH release.

Possible heart or blood-vessel concern based on animal data. Human risk is not clear.

Unknown effects on hormone-sensitive tissues with long-term exposure.

Product quality risk. No kisspeptin product is FDA-approved, and FDA reviewers flagged limited public data on kisspeptin-10 impurities.

Regulatory safety context

In October 2024, an FDA advisory committee voted against adding kisspeptin-10 to the 503A Bulks List. The review pointed to limited safety and effectiveness data, no approved product anywhere in the world, no major pharmacy-standard monograph, signal fade with chronic dosing, and concerning animal finding

Kisspeptin Timeline & What to Monitor
Kisspeptin usually produces a fast LH and FSH signal. LH and FSH are pituitary hormones. LH is the main signal that can tell the testes to make testosterone. In IVF trigger studies, one subcutaneous kisspeptin-54 dose raised LH for several hours. Kisspeptin-10 is faster and shorter.

Reported Response Windows

Form                                     Onset                        Peak                                           Return to baseline
Kisspeptin-10 (IV bolus)        Minutes                     ~10-30 min                                        <1 hour
Kisspeptin-10 (SC bolus)       <30 min                     ~30-60 min                                      Several hours
Kisspeptin-54 (SC bolus)       ~30 min                     ~5 hours (LH)                                  12-14 hours
Kisspeptin-54(IV infusion)      Minutes                    Varies with rate Within                  ~4 hours of stopping

These windows are based on published LH response data. Testosterone, when it changes, usually lags behind LH.

What is reasonable to monitor
Total testosterone (men): check before a cycle, then again on a steady schedule if testosterone response is the research question.
LH and FSH: these show whether the brain-pituitary signal is responding.
Estradiol: this estrogen marker can affect LH response, especially in women.
SHBG and free testosterone: useful context when total testosterone changes.
Sleep, mood, libido, and sexual-function notes: useful subjective markers, especially because kisspeptin has been studied in low-desire research.

Stopping or review points
If LH or FSH response fades during a cycle, that may be desensitization. If testosterone does not change even when LH rises, the issue may be downstream at the testes. More kisspeptin is not always the answer.

Kisspeptin Clinical Evidence Context
Kisspeptin has more human research than many research-use peptides. Still, the studies are narrow. Most focus on fertility, missing menstrual cycles from low hormone signaling, IVF triggering, and low sexual desire. The evidence is much thinner for general hormone optimization or post-cycle therapy.

IVF oocyte maturation trigger (kisspeptin-54)
IVF studies used kisspeptin-54 to help eggs mature before collection. In these studies, kisspeptin-54 triggered egg maturation and may have lowered OHSS risk compared with hCG. OHSS is ovarian hyperstimulation syndrome, a serious IVF complication.

Hypoactive sexual desire disorder (HSDD)
HSDD means low sexual desire that causes distress. In small men and women studies, IV kisspeptin-54 changed sexual brain response and some arousal measures compared with placebo.

Hypothalamic amenorrhea
Hypothalamic amenorrhea means missing periods because the brain is not sending enough hormone signal. Subcutaneous kisspeptin-54 has helped restore LH pulses in this setting, but repeated dosing can make the response fade.

Direct HPG-axis pharmacology in healthy adults
Direct head-to-head studies compared IV kisspeptin-10, IV kisspeptin-54, and IV GnRH in healthy men. GnRH raised LH more strongly, while kisspeptin-10 and kisspeptin-54 produced similar short-term LH responses.

Testosterone effect in men
In one healthy-men study, longer kisspeptin-10 infusion raised LH and also raised testosterone. Shorter 75-minute kisspeptin-54 studies raised LH/FSH but did not show a testosterone rise during that short window.

What has not been done
There is no completed Phase 3 trial, no FDA-approved kisspeptin product, and no strong long-term safety dataset. Claims about testosterone optimization, PCT, or long-term hormone support are still extrapolations